Perspective from Lynda Mitchell, MA, CAE The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating anaphylaxis and other type 1 ...

A groundbreaking wireless implant promises real-time, personalized pain relief using AI and ultrasound power no batteries, no ...

Scientists have created tiny disk-shaped particles that can swim on their own when hit with light, akin to microscopic robots ...

Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll ...

Revuforj is designed to treat patients with relapsed or refractory mutant NPM1 acute myeloid leukemia. The application has been assigned a real-time oncology review, which allows for a more efficient ...

While there's little disagreement that speeding drug approvals would be a good thing, there are more questions than answers ...

The FDA plans to approve selected high-priority drug application submissions in 1 to 2 months rather than 10 to 12.

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...